Active multiple myeloma suppresses and typically eliminates coexisting MGUS by Campbell, John et al.
 
 
Active multiple myeloma suppresses and typically
eliminates coexisting MGUS
Campbell, John; Heaney, Jennifer; Pandya, Sankalp; Afzal, Zaheer; Kaiser, Martin F; Owen,
Roger G; Child, J Anthony; Gregory, Walter M; Morgan, Gareth J; Jackson, Graham H;
Bunce, Christopher; Drayson, Mark
DOI:
10.1038/bjc.2017.229
License:
Creative Commons: Attribution-NonCommercial-ShareAlike (CC BY-NC-SA)
Document Version
Publisher's PDF, also known as Version of record
Citation for published version (Harvard):
Campbell, J, Heaney, J, Pandya, S, Afzal, Z, Kaiser, MF, Owen, RG, Child, JA, Gregory, WM, Morgan, GJ,
Jackson, GH, Bunce, C & Drayson, M 2017, 'Active multiple myeloma suppresses and typically eliminates
coexisting MGUS', British Journal of Cancer, vol. 117, pp. 835-839. https://doi.org/10.1038/bjc.2017.229
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
Copyright: 2017 Cancer Research UK. All rights reserved 0007 – 0920/17
10.1038/bjc.2017.229
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Feb. 2019
Active multiple myeloma suppresses and
typically eliminates coexisting MGUS
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Background: Myeloma is consistently preceded by premalignant monoclonal gammopathy of undetermined significance
(MGUS). In 45% of MGUS patients there is a second MGUS clone (biclonal gammopathy of undetermined significance; BGUS),
yet, at myeloma diagnosis, presentation of biclonal gammopathy myeloma (BGMy) is considered less frequent, implying that
myeloma eradicates coexisting MGUS.
Methods: In the largest study of its kind, we assessed BGMy frequency amongst 6399 newly diagnosed myeloma patients enrolled
in recent UK clinical trials.
Results: Compared to expected prevalence (i.e.,45% of MGUS have BGUS), only 58 of 6399 (0.91%) newly diagnosed myeloma
patients had BGMy, indicating myeloma typically eliminates coexistent MGUS. In these 58 BGMy cases, the MGUS plasma cell
clone was greatly suppressed in size compared to typical levels observed in conventional MGUS; contrarily, the MGUS clone did
not inhibit the myeloma plasma cell clone in BGMy.
Conclusion: Myeloma eliminates the majority of competing MGUS, and when it does not, the MGUS clone is substantially
reduced in size.
Myeloma and the asymptomatic precursor that consistently
precedes it, monoclonal gammopathy of undetermined significance
(MGUS) (Landgren et al, 2009; Weiss et al, 2009), are characterised
by monoclonal plasma cells (PCs) in the bone marrow and
monoclonal antibody (MAB) in blood. In a population-based study
of 12 482 persons, prevalence of MGUS was 3.7% in blacks, 2.3% in
whites and 1.8% in Hispanics, and within these MGUS popula-
tions, the prevalence of two MGUS clones–termed biclonal
gammopathy of undetermined significance (BGUS) (Kyle et al,
1981)–was 15.4%, 6.8% and 12.8%, respectively (Landgren et al,
2014). A proportion of new myeloma diagnoses also exhibit two
MABs in immunofixation electrophoresis (IFE), termed myeloma
with biclonal gammopathy (BGMy). This represents progression of
one BGUS clone to active myeloma and the continued presence of
a secondary MGUS clone (Kyle et al, 1981; Kyle et al, 2003). Given
that the prevalence of MGUS in the general population–at the
mean age of myeloma diagnosis–is B5% (Dispenzieri et al, 2010;
Wadhera and Rajkumar, 2010), and prevalence of BGUS amongst
all MGUS is 45% (Landgren et al, 2014), one would also expect
more than 5% of myeloma cases to be BGMy. The frequency of
BGMy remains uncertain (Kyle et al, 1981; Nilsson et al, 1986;
Riddell et al, 1986; Guastafierro et al, 2012; Garcia-Garcia et al, 2015).
In a review of 1027 myeloma diagnoses in one centre, 2% of cases
were BGMy (Kyle et al, 2003). This lower than expected figure
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warrants validation as it implies that when myeloma arises in an
individual with BGUS, the malignant myeloma clone eliminates the
competing MGUS clone. Here, in the largest study of its kind, we
assessed 6399 newly diagnosed myeloma patients entered into three
multicentre UK clinical trials to determine the frequency, and MAB
sizes of, BGMy at myeloma diagnosis.
MATERIALS AND METHODS
Trial patients. The BGMy patients were identified from 6399
newly diagnosed myeloma patients enrolled in one of the following
multicentre, phase III trials: the UK MRC Myeloma IX trial
(N¼ 1693; ISRCTN68454111); the CRUK Myeloma XI trial up to
an induction randomisation date of 23 July 2015 (N¼ 3880;
ISRCTN49407852); or the UK NIHR TEAMM Trial up to a
randomisation date of 23 July 2015 (N¼ 826; ISRCTN51731976).
All patients gave written informed consent. The study was
approved by the institutional review boards of the participating
centres and was conducted according to the Declaration of
Helsinki and the International Conference on Harmonization
Guidelines for Good Clinical Practice.
Laboratory tests. The MABs in serum were identified by IFE (Sebia,
Paris, France) and quantified by protein zone electrophoresis and
densitometry (SPE; Interlab, Rome, Italy); please refer to
Supplementary Information for more information. In patients with
a light-chain (LC) MAB without a heavy-chain (HC) component (i.e.,
LC-only myeloma), MAB size was measured and monitored by
involved free LCs (Binding Site, Birmingham, UK) expressed in g l 1.
Statistical analyses. Differences between groups were analysed by
one-way ANOVA for continuous variables (e.g., MAB size), and w2
for categorical variables and frequencies. One-sample t-tests were
used to compare observed MAB sizes to previously observed mean
MAB sizes in the literature; observed BGMy MAB sizes were
compared to reported MAB sizes in MGUS (Turesson et al, 2014)
and myeloma using a combined data set from MIX and MXI UK
trials. Correlational analyses were conducted using Pearson’s for
normally distributed data and Spearman’s Rank where data was
skewed. Significance was accepted at Po0.05. Data were analysed
by IBM SPSS statistics version 21 (Armonk, NY, USA).
RESULTS
Frequency of BGMy and demographics of BGMy patients. A
total of 58 patients had BGMy (from MIX¼ 18, MXI¼ 33 and
TEAMM¼ 7) and 6341 had monoclonal gammopathy myeloma
(MGMy) giving a BGMy frequency of 58 out of 6399 patients
(0.91%; 99% confidence interval: ±0.3%). Comparison of the 58
BGMy patients with MGMy patients in the same trials found no
differences in age: BGMy median age (range) was 69 (45–86) years;
and MGMy was 66 (28–90) years.
Distinguishing MGUS from myeloma MABs. The frequencies
and concentrations of serum MABs in all 58 BGMy patients at trial
entry are presented in Table 1; the largest MAB is classified as the
myeloma MAB and is referred to as ‘M1’, whereas the smaller
MAB was classified as the MGUS MAB and is referred to as ‘M2’.
In 4 patients with a FLC MAB 4500mg l 1 and intact
Table 1. Characteristics and frequencies of M1 and M2 in 58 BGMy patients at myeloma diagnosis, compared to expected
frequencies and characteristics of MGMy and conventional MGUS
MAB 1 MAB 2
HC isotype
Frequency
(N)
Proportion
(%)
Conc. (g l1)
(median (range))
MGMy reference rangesa HC isotype
Frequency
(N)
Proportion
(%)
Conc. (g l1)
(median (range))
MGUS reference rangesb
Proportion
(%)
Conc. (g l1)
(median (range))
Kyle et al,
2006
Turesson et al, 2014
Proportion (%)
Conc. (g l 1)
(median±s.d.)
IgG Total 39 67.2 c36.1 (4.8–70.0) 59.9 34.4 (0.8–100.2) IgG Total 33 56.9 d2.6 (0.5–12.0) 68.9 68.8 7.0±6.0
IgGk 26 66.7 32.6 (4.8–70.0) IgGk 17 51.5 2.5 (0.5–12.0)
IgGl 13 33.3 39.7 (10.2–60.0) IgGl 16 48.5 2.8 (0.5–9.0)
IgA Total 14 24.1 c25.4 (1.8–60.0) 23.6 33.0 (0.2–96.6) IgA Total 11 19.0 d1.7 (0.5–11.6) 10.8 14.7 8.0±5.0
IgAk 8 57.1 26.9 (1.8–60.0) IgAk 5 45.5 1.3 (0.5–3.9)
IgAl 6 42.9 23.2 (3.9–53.0) IgAl 6 54.5 2.5 (0.5–11.6)
IgD Total 1 1.7 2.6 (2.6–2.6) 1.7 4.2 (0.2–36.9) IgM Total 14 24.1 d1.3 (0.5–6.0) 17.2 16.2 7.0±6.0
IgDk 0 0.0 — IgMk 12 85.7 1.3 (0.5–6.0)
IgDl 1 100 2.6 (2.6–2.6) IgMl 2 14.3 1.6 (0.6–2.7)
FLC Total 4 6.9 1.0 (0.5–1.9) 13.1 2.6 (0.02–46.7)
FLCk 3 75.0 1.4 (0.5–1.9)
FLCl 1 25.0 0.7 (0.7–0.7)
LC isotype Frequency (N) Proportion (%) Conc. (g l 1)
(median (range))
MGMy reference proportiona (%) LC isotype Frequency (N) Proportion (%) Conc. (g l 1)
(median (range))
MGUS reference proportion (%) Kyle
et al, 2006
k 37 63.8 26.0 (0.5–70.0) 66.0 k 34 58.6 1.8 (0.4–12.0) 62.0
l 21 36.2 27.0 (0.7–60.0) 34.0 l 24 41.4 2.7 (0.5–11.6) 37.9
Abbreviations: BGMy¼biclonal gammopathy myeloma; Conc.¼ concentration; FLC¼ free light chain; HC¼heavy chain; LC¼ light chain; MAB¼monoclonal antibody; MGMy¼monoclonal
gammopathy myeloma; MGUS¼monoclonal gammopathy of undetermined significance.
aReference ranges aggregated from 3248 patients with MGMy diagnosed at entry into Myeloma IX and Myeloma XI trials; data set cutoff June 2013.
bReference ranges derived from 728 MGUS patients (Turesson et al, 2014) or 694 MGUS patients (Kyle et al, 2006).
cSignificant difference between M1 and M2 concentration (IgG Po0.001; IgA Po0.001).
dSignificant difference between M2 concentration and expected MAB concentration in MGUS (IgG Po0.001; IgA Po0.001; IgM Po0.001) (Turesson et al, 2014). No significant differences
observed between M1 and expected MAB concentrations in MGMy (P40.05) based on observations from Myeloma IX and XI.
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immunoglobulino5 g l 1, the FLC MAB was selected as M1. M1s
were 10- to 20-fold larger than M2s with median M1 IgG
34.4 g l 1 compared to M2 IgG 2.6 g l 1; and M1 IgA 33 g l 1
compared to M2 IgA 1.7 g l 1.
M1 and M2 MAB combinations in BGMy are presented in
Table 2 where it can be seen that 37 out of 58 BGMy (65%)
combinations exhibited different LC isotypes; assessment of
available serum FLC levels in these patients (illustrated in
Supplementary Figure 1) demonstrated that elevated FLC levels
were predominantly associated with the M1 clone.
In Table 2, we show that two independent IgG MABs was the
most common M1 and M2 combination (16 out of 58 patients),
but not as common as expected (27 out of 58), and we did not
observe any patients with two IgG MABs with the same LC isotype
(15 out of 58 expected; Po0.001; w2¼ 17.228). In 6 BGMy patients
with two IgG MABs, the electrophoretic mobilities of the MABs
were very similar and so these MABs were only reliably
distinguishable by their different LC isotype. Accordingly, we
may have missed a third of the 15 out of 58 expected IgG MAB
pairs of the same LC isotype, because of electrophoretic mobility
similarities.
MGUS MAB isotypes and levels in BGMy compared to
conventional MGUS. The most frequent M2 was IgG (33 out of
58), and a quarter of M2 clones (14 out of 58) secreted IgM. The
frequency of different M2 HC isotypes was closest to the patterns
observed in two MGUS studies of 728 and 694 MGUS patients,
rather than the different HC frequencies seen in myeloma (Kyle
et al, 2006; Turesson et al, 2014) (Table 1). There were, however,
less IgG M2s than would be expected in a typical MGUS
population (33 versus 41) and more IgM and IgA isotypes
(25 versus 16; trend observed: P¼ 0.092; w2¼ 2.83).
The level of the MGUS-associated MAB (M2) in BGMy was
smaller than sizes reported in MGUS (Turesson et al, 2014) by 2.5-
fold for IgG and 5-fold for IgA and IgM MABs (Po0.001). Thus,
whereas coexistent MGUS (i.e., M2) did not appear to suppress the
myeloma clone (i.e., M1) in BGMy, the presence of myeloma (M1)
significantly suppressed MGUS (M2) MAB levels. The magnitude
of this suppression is illustrated in Table 3 where 83% of M2’s were
below 5 g l 1 compared to the observed 24% in a prior MGUS
study.
Serum levels of myeloma MABs are the same in MGMy and
BGMy. The most prevalent M1 was IgG, followed by IgA, FLC
and then IgD; no IgM or IgE M1’s were observed; please refer to
Supplementary Information for more information. The HC
frequencies were very similar to those of 3248 patients in the
same clinical trials who had MGMy (Table 1). Notably, IgG and
IgA M1 MAB concentrations were not significantly different to
those observed in the MGMy patients from the same trials. This
indicates that the presence of a second neoplastic PC clone
(i.e., M2) does not competitively suppress the expansion of the
neoplastic myeloma clone (i.e., M1) (Table 3).
DISCUSSION
This is the largest study of BGMy frequency in a large cohort
of newly diagnosed myeloma patients, and demonstrates that
Table 2. Frequency of M1 and M2 combinations observed in
BGMy
MAB 1 MAB 2 MAB 2 frequency MAB 2 proportion
Observed
BGMy
frequency
(N)
Expected
MGUSa
frequency
(N)
Observed
BGMy
proportion
(%)
Expected
MGUSa
proportion
(%)
IgG k
(N¼ 26)
IgG k 0b 12 0 46
IgG l 10 6 38 23
IgA k 3 3 12 10
IgA l 4 1 15 5
IgM k 7 3 27 11
IgM l 2 1 8 5
IgG l
(N¼ 13)
IgG k 6 6 46 46
IgG l 0 3 0 23
IgA k 2 1 15 10
IgA l 2 1 15 5
IgM k 3 1 23 11
IgM l 0 1 0 5
IgA k
(N¼ 8)
IgG k 5 4 63 46
IgG l 1 2 13 23
IgA k 0 1 0 10
IgA l 0 0 0 5
IgM k 2 1 25 11
IgM l 0 0 0 5
IgA l
(N¼ 6)
IgG k 4 3 67 46
IgG l 2 1 33 23
IgA k 0 1 0 10
IgA l 0 0 0 5
IgM k 0 1 0 11
IgM l 0 0 0 5
Abbreviations: BGMy¼biclonal gammopathy myeloma; FLC¼ free light chain; MAB¼
monoclonal antibody; MGUS¼monoclonal gammopathy of undetermined significance.
Because of low frequency, data not shown from one patient with IgD MAB 1 and four
patients with FLC MAB 1.
aReference range proportions obtained from Turesson et al (2014), with assumed 2 : 1
proportion of kappa : lambda for each heavy-chain isotype.
bw2-analyses revealed significant differences between the observed frequency of IgGk pairs
in BGMy compared to those expected in MGUS (Po0.001; w2¼ 15.60). A trend (P¼ 0.065;
w2¼ 3.391) was observed for frequency of observed IgGl pairs in BGMy and those expected
in MGUS.
Table 3. Comparison of M1 and M2 concentrations in BGMy
with expected MAB sizes in conventional MGMy and in
MGUS
Size
M1
proportion
and
frequencya
Expected
proportion
in MGMy
(%)b,c
M2
proportion
and
frequency
Expected
proportion
in MGUS
(%)d
o4.99 g l1 7% (N¼4) 7 83% (N¼48) 24
5.00–9.99g l 1 7% (N¼4) 5 14% (N¼8) 19
10.00–14.99g l 1 7% (N¼4) 5 3% (N¼2) 33
15.00–19.99g l 1 7% (N¼4) 6 0% (N¼0) 18
20.00–24.99g l 1 13% (N¼7) 9 0% (N¼0) 5
425.00 g l 1 57% (N¼31) 68 0% (N¼0) 1
Abbreviations: BGMy¼biclonal gammopathy myeloma; MAB¼monoclonal antibody;
MGMy¼monoclonal gammopathy myeloma; MGUS¼monoclonal gammopathy of unde-
termined significance.
aExcludes four patients diagnosed with a FLC myeloma M1 (all four patients had a whole
MAB o4.99 g l 1).
bReference range represents aggregated data from patients with MGMy diagnosed at entry
into Myeloma IX and Myeloma XI trials.
cExcludes patients with FLC myeloma and non-secretory myeloma.
dReference range derived from 694 MGUS patients (Kyle et al, 2006).
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myeloma eliminates or greatly suppresses coexisting MGUS. As the
prevalence of MGUS in the general population – at the typical age
of myeloma diagnosis – isB5% (Dispenzieri et al, 2010; Wadhera
and Rajkumar, 2010) and the prevalence of BGUS amongst all
individuals with MGUS is 45% (Landgren et al, 2014), it would
also be expected that 45% of myeloma cases would be BGMy.
However, despite rigorous central laboratory analysis, it was found
to be just 0.91%.
This shortfall is unlikely to be the result of myeloma being
fivefold more likely to arise in individuals with a single MGUS
clone than from individuals with two MGUS clones. A recent study
reported the rate of progression from BGUS to myeloma wasB1%
per year, which is similar to the incidence of MGUS progression to
myeloma (Mullikin et al, 2016). Thus, when myeloma arises from
BGUS, in B80% of cases, the other MGUS clone must be
eliminated or suppressed below the limits of detection on IFE
(0.1 g l 1).
In the BGMy cases reported herein, MGUS-associated MAB
levels were smaller than expected levels typically observed in
conventional MGUS (Turesson et al, 2014), by 2.5-fold for IgG and
5-fold for IgA and IgM. The degree of suppression of MGUS clones
in BGMy appears comparative to the immunoparesis of non-
malignant polyclonal PC that occurs in the majority of newly
diagnosed myeloma patients (Pruzanski et al, 1980; Wangel, 1987;
Wang and Young, 2001; Kastritis et al, 2014). Of 3248 MGMy
patients from the same Myeloma IX and XI trials reported in this
study, we found that polyclonal immunoglobulin levels were below
the normal range in 480% of patients and levels were lower than
the median level found in healthy controls by 2.5-fold for IgG and
7-fold for IgA and IgM. Despite their larger relative presence,
MGUS clones appear to only compete effectively with polyclonal
PC inB20% of cases, as evidenced by incidence of immunoparesis
in MGUS (Turesson et al, 2014). As only a fifth of MGUS clones
exhibit competitiveness for the normal PC niche, we hypothesise
that these are the only MGUS clones that survive when myeloma
arises in the wider marrow environment and that they are subject to
the same suppression of clonal size and antibody secretion as
normal polyclonal PCs; this would also be applicable to the MGUS
PC clone from which myeloma arose. In a separate observation, we
observed in this study that two IgG MABs was the most common
BGMy combination (16 out of 58 patients) but not as common as
expected (27 out of 58) indicating that the presence of IgG myeloma
PC clones suppresses IgG MGUS PC clones more than IgA or IgM
PC clones. There is evidence from both MGUS and myeloma that
neoplastic IgG PC clones exert a greater degree of suppression on
normal polyclonal IgG PC than they do on IgA and IgM isotypes
(Bradwell et al, 2013; Katzmann et al, 2013; Ludwig et al, 2016).
A limitation of our study is that we were unable to conduct
longitudinal measurement of BGUS before myeloma diagnosis; this
excluded the possibility of investigating elimination of MGUS
clones at the time of myeloma clone proliferation. Future
prospective studies may seek to explore differences between BGUS
that progress to myeloma, and BGUS that do not progress to
myeloma, and measurements should incorporate bone marrow
tumour samples as well as stroma to investigate possible
mechanisms of tumour eradication. In summary, our findings
confirm that BGMy is rare, and the survival of a coexisting MGUS
clone is hallmarked by reduced MAB size.
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